The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

ST Elevation Myocardial Infarction Clinical Trial

Official title:

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in Patients With ST-elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03740776
• Other study ID #: 2018-35
• Status: Completed
• Start date: October 1, 2015
• Est. completion date: November 1, 2018

Study information

• Verified date: November 2018
• Source: Chongqing Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Eosinophils (EOS) in peripheral blood are significantly decreased in ST-segment elevation myocardial infarction (STEMI) and the reduced EOS indicates severe myocardial damage. Whether EOS is a good predictor for in-hospital major adverse cardiac events (MACEs) of patients with ST-segment elevation myocardial infarction remains unknown. The aims of this study was to evaluate prognostic role of EOS for in-hospital MACEs in STEMI patients who have undergone primary percutaneous coronary intervention (PCI)

Description:

The investigators retrospectively analyzed the clinical data of 518 patients with STEMI after PCI. MACEs were defined as cardiac arrest, cardiac rapture, malignant arrhythmia and cardiac death. The receiver operating characteristic (ROC) curves were used to demonstrate the prognostic value of EOS% in in-hospital MACEs. All patients were divided into 2 groups according to the best cut-off EOS% value, including reduced EOS% group and control group. Cox regression analyses and KM survival curve were used to calculate the correlated between EOS with in-hospital MACEs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: November 1, 2018
• Est. primary completion date: August 1, 2017
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patients with STEMI who underwent PCI within 12 hours from symptom onset

2. Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion Criteria:

1. Patients with previous myocardial infarction, congenital heart disease

2. Patients with liver disease, and renal failure

3. Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Dongying Zhang

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	major adverse cardiac events	the relationship between reduced eosinophils percentage and in-hospital MACE	The median time of 7 days